Candriam SCA’s Vanda Pharmaceuticals VNDA Stock Holding History

Candriam SCA’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-266,000	Closed	-$4.27M	–	876
2020 Q1	$4.27M	Hold	266,000	–	–	0.05%	390
2019 Q4	$4.37M	Sell	266,000 -5,000	-2%	-$75.6K	0.05%	402
2019 Q3	$3.6M	Hold	271,000	–	–	0.05%	385
2019 Q2	$3.8M	Hold	271,000	–	–	0.05%	394
2019 Q1	$4.99M	Buy	271,000 +93,000	+52%	+$2.12M	0.06%	328
2018 Q4	$4.65M	Buy	+178,000	New	+$4.19M	0.07%	295
2017 Q3	–	Sell	-170,000	Closed	-$2.77M	–	748
2017 Q2	$2.77M	Sell	170,000 -67,000	-28%	-$966K	0.05%	394
2017 Q1	$3.32M	Hold	237,000	–	–	0.06%	346
2016 Q4	$3.78M	Buy	237,000 +20,000	+9%	+$321K	0.09%	256
2016 Q3	$3.61M	Buy	+217,000	New	+$2.92M	0.09%	248

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Candriam SCA's VNDA Position: Q2 2020 in Review

Candriam SCA sold out of Vanda Pharmaceuticals (VNDA) in Q2 2020, closing a stake of 266,000 shares — an estimated $4.27M sold.

Candriam SCA first reported a position in VNDA in Q3 2016 and held it in 10 quarters. The position peaked at $4.99M in Q1 2019. 164 funds tracked by Wall St. Rank hold VNDA as of Q2 2020.

Candriam SCA reported no remaining Vanda Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Candriam SCA sold 266,000 Vanda Pharmaceuticals shares in Q2 2020, an estimated $4.27M.
Candriam SCA first reported a position in Vanda Pharmaceuticals in Q3 2016 and held it in 10 quarters.
Candriam SCA's Vanda Pharmaceuticals position peaked at $4.99M in Q1 2019.
164 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2020.

Based on Candriam SCA's 13F filing for Q2 2020, filed 23 Jul 2020.